Is widespread screening for hepatitis C justified?

  title={Is widespread screening for hepatitis C justified?},
  author={Ronald L. Koretz and Kenneth Weicong Lin and John P. A. Ioannidis and Jeanne Lenzer},
  journal={BMJ : British Medical Journal},
Several organisations have recommended greatly expanded screening for hepatitis C infection. Ronald Koretz and colleagues are concerned that no study has tested whether this will lead to net clinical benefit or harm in screened populations 

Screening and treatment for hepatitis C: a balanced perspective

A contrasting view based on four key points is offered on a randomised trial of hepatitis C screening on the basis of a selective literature review.

Should Family Physicians Routinely Screen Patients for Hepatitis C? No: One-time Screening Still Has Too Many Unanswered Questions.

  • K. Lin
  • Medicine
    American family physician
  • 2016
Given current scientific uncertainties, limited resources, and evolving guidelines, a reasonable middle ground would be to focus HCV testing and therapy on patients who are most likely to have

Early diagnosis and treatment: the goal of hepatitis C screening

The need for robust evidence for hepatitis C screening is highlighted, but a few points warrant a more balanced discussion, and the US birth cohort screening programme should be considered.

USPSTF recommends screening adults 18 to 79 years for hepatitis C virus infection (moderate certainty)

  • R. Koretz
  • Medicine
    Annals of Internal Medicine
  • 2020
Screening for hepatitis C virus infection in adolescents and adults and US Preventive Services Task Force Recommendation Statement, 2020;323:970-5.

Efficacy of Direct-Acting Antivirals Compared with Older Agents for Hepatitis C.

Although they help patients achieve sustained viralogic response, expensive direct-acting antivirals have yet to show that they can succeed in meeting top-priority treatment goals.

NICE’s recommendation on sofosbuvir for hepatitis C

Koretz and colleagues point out that new hepatitis C drugs need to be evaluated by long term follow-up of clinical outcomes and not just surrogate markers.1 However, the National Institute of Health

Hepatitis C screening of men who have sex with men

Koretz and colleagues failed to highlight hepatitis C (HCV) as an emerging sexually transmitted infection in men who have sex with men (MSM), and the public health implications.1 The past decade has

Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justified

The authors argue that because a community study showed an increase in liver and non-liver mortality most infected people will not die from HCV, and screening should be delayed.

Hepatitis C in a prison in the North East of England: what is the economic impact of the universal offer of testing and emergent medications?

Testing for hepatitis C virus infections in people who inject drugs and in prescribed places of detention for PPDs shows positive results for sofosbuvir and ledipasvir-SFOV, respectively.

Centers for Disease Control and Prevention: protecting the private good?

  • J. Lenzer
  • Business
    BMJ : British Medical Journal
  • 2015
After revelations that the CDC is receiving some funding from industry, Jeanne Lenzer investigates how it might have affected the organisation’s decisions



Curing chronic hepatitis C--the arc of a medical triumph.

The development of direct-acting antiviral agents has revolutionized the treatment of hepatitis C by offering genuine prospects for a comprehensive cure of a chronic viral infection. This success can

Natural history of hepatitis C in thalassemia major: a long‐term prospective study

The natural history of post‐transfusional hepatitis C in thalassemia major is evaluated, paying special attention to spontaneous viral clearance, to factors influencing the chronicity rate and fibrosis progression.

Review article: genetic factors that modify the outcome of viral hepatitis

Genetic factors can play an important role in treatment response and disease progression in chronic viral hepatitis and should be considered in the selection of patients for hepatitis B virus infection.

Screening for Hepatitis C Virus Infection in Adults: A Systematic Review for the U.S. Preventive Services Task Force

Although screening tests can accurately identify adults with chronic HCV infection, targeted screening strategies based on the presence of risk factors misses some patients withHCV infection.

Therapy for hepatitis C--the costs of success.

Three large, controlled trials of different regimens of oral antiviral agents for chronic hepatitis C, genotype 1, yielded rates of sustained virologic response of 93% to 99%.

Management of hepatitis C.

The management of special groups, including those with acute HCV infection, co-infected with hepatitis B (HBV) or human immunodeficiency virus (HIV), continues to be defined.

Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement

  • V. Moyer
  • Medicine
    Annals of Internal Medicine
  • 2013
The Agency for Healthcare Research and Quality commissioned 2 systematic reviews on screening for and treatment of HCV infection in asymptomatic adults, focusing on evidence gaps identified in the previous USPSTF recommendation and new studies published since 2004.

Birth cohort screening may help find hepatitis C cases.

The ASCO authors called for further studies of palliative care to evaluate its optimaltiming,venue, and components; reimbursement models to facilitate its use; its application ofindiseases other thanlung cancer; and itffects the continuum of care, especially during the delivery of antitumor therapy.

Ribavirin plus interferon versus interferon for chronic hepatitis C.

Compared withinterferon alone, ribavirin plus interferon is more effective in clearing hepatitis C virus and improving liver histology, which may lead to reduced morbidity and mortality, however, combination therapy significantly increased the risk of several adverse events.